NCT01665794View on ClinicalTrials.gov

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

August 13, 2012

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Pomalidomide

Pomalidomide taken orally at assigned dose.

DRUG

Carfilzomib

Carfilzomib given by intravenous (IV) infusion at assigned dose.

DRUG

dexamethasone

Dexamethasone taken orally of given by IV infusion.

DRUG

Daratumumab

Daratumumab given by intravenous (IV) infusion at assigned dose.

Trial Locations (5)

37203

Sarah Cannon Research Institute, Nashville

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Wayne State University - Karmonos Cancer Center, Detroit

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

MISG 2M9

University Health Network - Princess Margaret Cancer Center, Toronto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Multiple Myeloma Research Foundation

OTHER

lead

University of Chicago

OTHER

NCT01665794 - Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter